However, anti-PD-1/PD-L1 therapy is deemed ineffective for the majority of CRC patients, and only those with high MSI-H and a high mutation burden respond to the treatment (Kreidieh et al., 2020). This evidence concerns the gene PDCD1 and colorectal carcinoma.